Diclofenac oral solution - Depomed

Drug Profile

Diclofenac oral solution - Depomed

Alternative Names: Cambia; Catafast; Potassium diclofenac for oral solution; PRO-513; Voltfast

Latest Information Update: 10 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Applied Pharma Research
  • Developer Depomed; Novartis
  • Class Antirheumatics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Migraine

Most Recent Events

  • 28 Feb 2018 Depomed has patent protection for Diclofenac oral solution in Canada
  • 06 Mar 2017 Diclofenac oral solution licensed to DKSH in the Philippines, Malaysia, Myanmar and Vietnam for the treatment of Migraine
  • 19 Jan 2017 Diclofenac oral solution licensed to Renhe Group in China, Taiwan, Hong Kong and Macao for the treatment of Migraine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top